Marzia Capelletti
Caris Life Sciences (United States) · 299 works · 14,514 citations · h-index 42
Top works
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
- Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma